Zacks Investment Research downgraded shares of NantHealth (NASDAQ:NH) from a buy rating to a hold rating in a research report report published on Wednesday, December 20th.
According to Zacks, “Nant Health, LLC is a personalized healthcare company which enable improved patient outcomes and treatment decisions for critical illnesses. The company developed an adaptive learning system, CLINICS, which includes its unique software, middleware and hardware systems infrastructure that collects, indexes, analyzes and interprets of molecular, clinical, operational and financial data points derived from novel and traditional sources. Nant Health, LLC is based in CULVER CITY, United States. “
Several other research analysts also recently commented on NH. Jefferies Group reaffirmed a buy rating and set a $5.00 target price on shares of NantHealth in a report on Thursday, September 28th. Canaccord Genuity cut their target price on NantHealth from $6.00 to $5.00 and set a buy rating on the stock in a report on Friday, November 17th. Finally, BidaskClub downgraded NantHealth from a sell rating to a strong sell rating in a report on Wednesday, December 6th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $8.05.
NantHealth (NASDAQ NH) traded up $0.01 during midday trading on Wednesday, hitting $3.77. The company had a trading volume of 194,600 shares, compared to its average volume of 157,598. The company has a debt-to-equity ratio of 0.93, a quick ratio of 2.36 and a current ratio of 2.38. NantHealth has a 12 month low of $2.60 and a 12 month high of $10.19. The firm has a market cap of $407.32, a P/E ratio of -2.12 and a beta of -1.50.
NantHealth (NASDAQ:NH) last released its quarterly earnings data on Thursday, November 9th. The company reported ($0.13) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. NantHealth had a negative return on equity of 46.09% and a negative net margin of 225.76%. The company had revenue of $21.76 million for the quarter, compared to the consensus estimate of $29.42 million. During the same quarter last year, the business posted ($0.18) EPS. NantHealth’s revenue for the quarter was up 5.3% on a year-over-year basis. equities research analysts anticipate that NantHealth will post -1.35 EPS for the current year.
Several hedge funds have recently bought and sold shares of the company. GSA Capital Partners LLP raised its position in shares of NantHealth by 154.7% in the 3rd quarter. GSA Capital Partners LLP now owns 72,600 shares of the company’s stock worth $299,000 after acquiring an additional 44,100 shares in the last quarter. Highbridge Capital Management LLC raised its position in shares of NantHealth by 6.5% in the 3rd quarter. Highbridge Capital Management LLC now owns 250,000 shares of the company’s stock worth $1,030,000 after acquiring an additional 15,264 shares in the last quarter. National Planning Corp raised its position in shares of NantHealth by 21.1% in the 3rd quarter. National Planning Corp now owns 138,700 shares of the company’s stock worth $656,000 after acquiring an additional 24,200 shares in the last quarter. Dimensional Fund Advisors LP bought a new position in shares of NantHealth in the 3rd quarter worth about $365,000. Finally, Schwab Charles Investment Management Inc. bought a new position in shares of NantHealth in the 3rd quarter worth about $180,000. 7.10% of the stock is owned by hedge funds and other institutional investors.
WARNING: This report was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2018/01/14/nanthealth-nh-rating-lowered-to-hold-at-zacks-investment-research.html.
NantHealth, Inc is a healthcare cloud-based information technology (IT) company. The Company is engaged in converging science and technology through a single integrated clinical platform, to provide actionable health information at the point of care. The Company offers the Genomic Proteomic Spectrometry (GPS) Cancer test, a molecular test and decision support solution that measures the proteins present in the patient’s tumor tissue, combined with whole genomic and transcriptomic sequencing of tumor and normal samples.
Get a free copy of the Zacks research report on NantHealth (NH)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NantHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NantHealth and related companies with MarketBeat.com's FREE daily email newsletter.